determine whether A 3 adenosine receptor (A3AR) signaling modulates myocardial function, energetics, and cardioprotection, hearts from wild-type and A 3AR-overexpressor mice were subjected to 20-min ischemia and 40-min reperfusion while 31 P NMR spectra were acquired. Basal heart rate and left ventricular developed pressure (LVDP) were lower in A 3AR-overexpressor hearts than wild-type hearts. Ischemic ATP depletion was delayed and postischemic recoveries of contractile function, ATP, and phosphocreatine were greater in A 3AR-hearts. To determine the role of depressed heart rate and to confirm A3AR-specific signaling, hearts were paced at 480 beats/min with or without 60 nmol/l MRS-1220 (A 3AR-specific inhibitor) and then subjected to ischemiareperfusion. LVDP was similar in paced A 3AR-overexpressor and paced wild-type hearts. Differences in ischemic ATP depletion and postischemic contractile and energetic dysfunction remained in paced A3AR-overexpressor hearts versus paced wild-type hearts but were abolished by MRS-1220. In summary, A 3AR overexpression decreased basal heart rate and contractility, preserved ischemic ATP, and decreased postischemic dysfunction. Pacing abolished the decreased contractility but not the ATP preservation or cardioprotection. Therefore, A 3AR overexpression results in cardioprotection via a specific A 3AR effect, possibly involving preservation of ATP during ischemia. cardioprotection; ischemia; nuclear magnetic resonance spectroscopy ADENOSINE IS an endogenous metabolite that is released from the myocardium during ischemia-reperfusion.
cardioprotection; ischemia; nuclear magnetic resonance spectroscopy ADENOSINE IS an endogenous metabolite that is released from the myocardium during ischemia-reperfusion. Exogenous administration of adenosine or adenosine receptor agonists has been shown to be cardioprotective (20, 26) . Because of its potent cardioprotective effects, much attention has focused on the use of adenosine as a cardiotherapy. Thus far the main approach in therapy development has been to administer adenosine, adenosine receptor agonists, or modulators of adenosine degradation (15, 22) . Clinical use of such approaches is complicated by the effects of these agents on noncardiac tissue and by progressive desensitization of adenosine receptors. Cardiac-specific targeting could alleviate some of these problems. Therefore, a transgenic mouse model was recently developed with cardiac-specific overexpression of the G i/o -coupled A 1 adenosine receptor (A 1 AR) (23) . Hearts from these mice were inherently resistant to ischemia, indicating that increasing the number of functional adenosine receptors alone can enhance endogenous adenosine signaling and lead to cardioprotection.
Although it is thought that the cardioprotective effects of adenosine are mediated primarily via the A 1 AR, recent evidence suggests that signaling through the A 3 adenosine receptor (A 3 AR), which also couples to G i/o , could be protective (1, 28, 31) . Although levels of the A 3 AR are low in cardiac tissue from most species (29, 32) , A 3 AR overexpression could be useful as a genetic therapy. To determine whether cardiac-specific overexpression of the A 3 AR protects against ischemic injury, transgenic mice were created with a gene construct consisting of the canine A 3 AR cDNA under the control of the ␣-myosin heavy chain promoter (2) . It was demonstrated that, after in vivo regional ischemia and reperfusion, infarct size was lower in low copy number A 3 AR overexpressors than in wild-type mice, confirming that A 3 AR signaling could protect against myocardial necrosis (2) . In the present study, we determined whether cardiac-specific overexpression of the A 3 AR could also protect against postischemic contractile dysfunction after short periods of ischemia. Perfused hearts from A 3 AR-overexpressor and wildtype mice were subjected to 15-or 20-min global ischemia and 40-min reperfusion. Because adenosine has negative chronotropic effects (14) and cardioprotection has been related to preservation of ischemic ATP (8, 24, 27) and intracellular pH levels (5, 7, 19) , contractile parameters and energetics were also studied in the A 3 AR-overexpressor hearts. Furthermore, the canine A 3 AR-specific inhibitor, MRS-1220, was used to con-firm that any observations in the A 3 AR-overexpressor hearts were indeed due to A 3 AR signaling.
MATERIALS AND METHODS

Animals
Transgenic mice exhibiting cardiac-specific overexpression of the A3AR were created by microinjection of a transgene construct, containing canine A3AR cDNA under the control of the ␣-myosin heavy chain promoter, into the pronuclei of fertilized FVB/N mouse oocytes (2) . After embryo implantation, the presence of the transgene in the resultant founder mice was confirmed by Southern blot analysis and expression of canine A 3AR mRNA was determined by Northern blot analysis. A3AR levels were assessed in the transgenic lines by radioligand binding assays (2) .
In the present study, 15 heterozygous low copy number transgenic mice (A 3tg.1) and 16 of their wild-type littermates were used; all animals were treated in accordance with National Institutes of Health (NIH) guidelines and the "Guiding Principles for Research Involving Animals and Human Beings" of the American Physiological Society. Binding assays revealed 12.7 fmol/mg of G protein-coupled A 3ARs in A3tg.1 hearts and negligible levels in wild-type littermates. A3tg.1 hearts exhibited no evidence of cardiac abnormalities, as determined from morphological and histochemical analysis and determination of expression of hypertrophic marker genes (2).
Ischemia-Reperfusion Protocol
Hearts were isolated and perfused in the Langendorff mode as described previously (4) . Hearts were then subjected to 20 min of no-flow ischemia followed by 40-min reperfusion. Left ventricular developed pressure (LVDP), rate of contraction (ϩdP/dt), rate of relaxation (ϪdP/dt), and heart rate were monitored via a water-filled latex balloon in the left ventricle. Recovery of contractile function was assessed by measurement of LVDP at the end of reperfusion and expressed as a percentage of preischemic LVDP.
Control Hearts, Pacing Protocol, and MRS-1220 Treatment
A control group of untreated A 3tg.1 (n ϭ 5) and wild-type (n ϭ 6) hearts was allowed to beat at their intrinsic heart rate, and another group of A 3tg.1 (n ϭ 5) and wild-type (n ϭ 5) hearts was paced throughout preischemia, and reperfusion at 8 Hz with a 4-ms square pulse generated by a Grass stimulator (Grass-Telefactor). We found that pacing itself increased ischemic injury (unpublished observations); therefore, the ischemic period was reduced to 15 min in the paced hearts to provide a suitable level of postischemic recovery of contractile function. A further group of A 3tg.1 (n ϭ 5) and wild-type (n ϭ 5) hearts was paced at 8 Hz and then treated with 60 nmol/l of the canine A 3AR-specific inhibitor MRS-1220, beginning 5 min before the 15-min ischemic period and continuing throughout reperfusion.
NMR Spectroscopy
Relative changes in concentrations of phosphorus metabolites were observed during the ischemia-reperfusion protocols by acquiring consecutive 31 P NMR spectra as described previously (6) . The areas of the spectral peaks were expressed as a percentage of the peak areas of an initial, preischemic control spectrum from each heart. Intracellular pH was estimated from the chemical shift of the P i peak relative to phosphocreatine (PCr) with previously obtained titration curves.
Statistics
Results are expressed as means Ϯ SE. Significance (P Յ 0.05) was determined for discrete variables by one-way analysis of variance and for continuous variables by analysis of variance for repeated measures; both analyses were followed by a Fisher's post hoc test.
RESULTS
Basal Contractile Function
During the preischemic period, LVDP was lower in unpaced A 3 AR-overexpressor hearts (87 cmH 2 O) than in unpaced wild-type hearts (110 cmH 2 O) (P Ͻ 0.0001; Table 1 ). Heart rate was also lower 319 beats/minute in unpaced A 3 AR-overexpressor hearts than in unpaced wild-type hearts (390 beats/min). ϩdP/dt (2.8 cmH 2 O/ms in A 3 AR overexpressors vs. 3.9 cmH 2 O/ms in wild type) and ϪdP/dt (Ϫ2.1 cmH 2 O/ms in A 3 AR overexpressors vs. Ϫ3.0 cmH 2 O/ms in wild type) (P Ͻ 0.001; Table 1 ) were also lower in unpaced A 3 AR-overexpressor hearts than in unpaced wild-type hearts. Thus basal myocardial contractility was decreased by overexpression of the A 3 AR.
On pacing at 480 beats/min, LVDP increased in A 3 AR-overexpressor hearts to 109 cmH 2 O (P Ͻ 0.0001 vs. unpaced A 3 AR overexpressors), whereas LVDP did 
Wild type
Data are means Ϯ SE, A3AR, A3 adenosine receptor; A3, A3AR overexpressor; LVDP, left ventricular developed pressure; ϩdP/dt, rate of contraction; ϪdP/dt, rate of relaxation. * Significant difference from corresponding wild-type group (P Ͻ 0.001); † significant difference between postinfusion and corresponding preinfusion value (P Ͻ 0.05).
not differ in paced versus unpaced wild-type hearts (Table 1) . ϩdP/dt and ϪdP/dt were also increased by pacing in A 3 AR-overexpressor hearts, to 3.8 cmH 2 O/ms and Ϫ2.8 cmH 2 O/ms, respectively. The increase in LVDP, ϩdP/dt, and ϪdP/dt in paced A 3 AR-overexpressor hearts resulted in these values not being significantly different from those of paced or unpaced wildtype hearts (Table 1) .
Pretreatment of paced hearts with 60 nmol/l of the A 3 AR-specific inhibitor MRS-1220 had no effect on LVDP, ϩdP/dt, or ϪdP/dt in either A 3 AR-overexpressor or wild-type hearts (Table 1) .
Postischemic Contractile Recovery
Recovery of contractile function after 20-min ischemia and 40-min reperfusion was higher in unpaced A 3 AR-overexpressor hearts (56% initial LVDP) than in unpaced wild-type hearts (30% initial LVDP) (P Ͻ 0.0001; Fig. 1 ). Postischemic contractile function was also higher in absolute terms in unpaced A 3 AR hearts (49 Ϯ 2 cmH 2 O) than in unpaced wild-type hearts (33 Ϯ 4 cmH 2 O) (P Ͻ 0.05).
In paced hearts, recovery of contractile function after 15-min ischemia and 40-min reperfusion was also higher in A 3 AR overexpressors (60% initial LVDP) than in wild type (35% initial LVDP) (P Ͻ 0.001; Fig.  1 ). Postischemic contractile function was also higher in absolute terms in paced A 3 AR hearts (65 Ϯ 4 cmH 2 O) than in paced wild-type hearts (39 Ϯ 6 cmH 2 O) (P Ͻ 0.001).
Pretreatment with 60 nmol/l MRS-1220 lowered functional recovery after 15-min ischemia and 40-min reperfusion in paced A 3 AR-overexpressor hearts to 27% initial LVDP (P Ͻ 0.0001 vs. untreated paced A 3 AR overexpressors), which was not significantly different from that observed in untreated paced wild-type hearts (35% initial LVDP) or MRS-1220-treated paced wild-type hearts (28% initial LVDP) (Fig. 1) . Postischemic LVDP was also lower, at 40 Ϯ 6 cmH 2 O, in MRS-1220-treated versus untreated paced A 3 AR-overexpressor hearts (P Ͻ 0.0001). Pretreatment with MRS 1220 had no significant effect on percent recovery of contractile function (28% initial LVDP) or absolute LVDP (29 Ϯ 6 cmH 2 O) in paced wild-type hearts.
Phosphate Metabolites and Intracellular pH
Phosphate metabolites and intracellular pH were measured in the transgenic and wild-type hearts to determine whether overexpression of the A 3 AR altered myocardial energetics and pH regulation.
ATP levels. During ischemia, ATP depletion was delayed in the unpaced A 3 AR-overexpressor hearts compared with wild-type hearts ( Fig. 2A) , but by the end of 20-min ischemia, ATP levels were the same in unpaced A 3 AR-overexpressor and wild-type hearts, both at ϳ20% initial ATP. By the end of reperfusion, ATP had increased to a greater extent in unpaced A 3 AR-overexpressor hearts, which reached 50% initial ATP, than in unpaced wild-type hearts, which reached 24% initial ATP (P Ͻ 0.01; Fig. 2A) .
In hearts paced at 480 beats/min, similar to the unpaced hearts, ischemic ATP depletion was delayed in the A 3 AR overexpressors compared with wild type. However, the shorter 15-min ischemic period used in the paced heart experiments resulted in ATP levels being significantly higher at the end of ischemia in paced A 3 AR-overexpressor hearts (41% initial ATP) than in paced wild-type hearts (20% initial ATP) (P Ͻ 0.05; Fig. 3A ). During reperfusion, ATP increased to a greater extent in paced A 3 AR-overexpressor hearts, which reached 63% initial ATP by the end of 40-min reperfusion, than in paced wild-type hearts, which reached 35% initial ATP (P Ͻ 0.01; Fig. 3A) .
Pretreatment with 60 nmol/l MRS-1220 abolished the delay in ATP depletion during ischemia in the paced A 3 AR-overexpressor hearts (Fig. 3A) . Correspondingly, ATP levels were 22% of initial ATP by the end of 15-min ischemia in the paced A 3 AR-overexpressor hearts (P Ͻ 0.05 vs. untreated paced A 3 AR overexpressors), which was not significantly different from that observed in untreated paced wild-type hearts (20% initial ATP) or MRS-1220-treated paced wildtype hearts (23% initial ATP). Pretreatment with MRS-1220 had no significant effect on ischemic ATP levels in paced wild-type hearts. Pretreatment with MRS-1220 also abolished the increased ATP recovery during reperfusion in paced A 3 AR-overexpressor hearts, end-reperfusion ATP levels being 28% of initial ATP in MRS-1220-treated paced A 3 AR-overexpressor hearts (P Ͻ 0.001 vs. untreated paced A 3 AR overexpressors), which was not significantly different from that observed in untreated paced wild-type hearts (35% initial ATP) or MRS-1220-treated paced wildtype hearts (30% initial ATP). Pretreatment with MRS-1220 had no significant effect on reperfusion ATP levels in paced wild-type hearts.
To further analyze the delay in ATP depletion in paced and unpaced A 3 AR-overexpressor hearts compared with wild-type hearts, the rates of ATP depletion during the first 15 min of ischemia were calculated. Pacing increased the rate of ATP depletion in both A 3 AR-overexpressor and wild-type hearts from Ϫ3.6 Ϯ 0.8% initial ATP/min in unpaced A 3 AR-overexpressor hearts to Ϫ5.4 Ϯ 0.4% initial ATP/min in paced A 3 ARoverexpressor hearts (P Ͻ 0.05) and from Ϫ5.1 Ϯ 0.2% initial ATP/min in unpaced wild-type hearts to Ϫ7.1 Ϯ 0.4% initial ATP/min in paced wild-type hearts (P Ͻ 0.05). Confirming the delay in ATP depletion in A 3 ARoverexpressor versus wild-type hearts, the rate of ATP depletion was significantly lower in both unpaced A 3 AR-overexpressor versus unpaced wild-type hearts (P Ͻ 0.05) and paced A 3 AR-overexpressor versus paced wild-type hearts (P Ͻ 0.05).
PCr levels. During ischemia, PCr levels fell in all hearts. At the end of ischemia, there were no differences in PCr levels (ϳ5% initial PCr) between unpaced A 3 AR-overexpressor and wild-type hearts (Fig. 2B) or between any of the paced groups, all also at ϳ5% of initial PCr (Fig. 3B) . Although PCr levels were not different during early reperfusion, by the end of reperfusion PCr levels had increased to a greater extent in unpaced A 3 AR-overexpressor hearts, which reached 66% of initial PCr, than in unpaced wild-type hearts, which reached 42% of initial PCr (P Ͻ 0.05; Fig. 2B) .
In paced hearts, reperfusion PCr levels recovered to a greater extent in A 3 AR-overexpressor hearts, which reached 107% of initial PCr by the end of reperfusion, than in wild-type hearts, which reached 74% of initial PCr (P Ͻ 0.001; Fig. 3B ).
Pretreatment with MRS-1220 abolished the increased PCr recovery during reperfusion in paced A 3 AR-overexpressor hearts, end-reperfusion PCr levels being 67% of initial PCr in MRS-1220-treated paced A 3 AR-overexpressor hearts (P Ͻ 0.001 vs. untreated paced A 3 AR overexpressors), which was not significantly different from that observed in untreated paced wild-type hearts (74% initial PCr) or MRS-1220- treated paced wild-type hearts (62% initial PCr). Pretreatment with MRS-1220 had no significant effect on reperfusion ATP levels in paced wild-type hearts.
Intracellular pH. During ischemia, pH decreased in all hearts. At the end of ischemia, there were no differences in pH levels, at pH ϳ5.80, between unpaced A 3 AR-overexpressor and wild-type hearts (Fig. 2C) or between any of the paced groups, all also at pH ϳ5.80 (Fig. 3C) . During reperfusion, pH increased in all hearts back to preischemic values. At the end of reperfusion, there were also no differences in pH levels, at pH ϳ7.10, between unpaced A 3 AR-overexpressor and wild-type hearts (Fig. 2C) or between any of the paced groups, all at pH ϳ7.10 (Fig. 3C) .
DISCUSSION
Effect of A 3 AR Overexpression on Heart Rate, Basal Contractility, Energetics, and Postischemic Dysfunction
In the present study, preischemic heart rate, peak contraction (LVDP), ϩdP/dt, and ϪdP/dt were lower in perfused hearts from A 3 AR-overexpressor mice than wild-type mice (Table 1) . This observation of A 3 ARinduced negative chronotropy and inotropy is reminiscent of that induced by exogenous adenosine or by overexpression of the A 1 AR (14, 23). The A 3 AR-overexpressor and wild-type hearts were then subjected to 20-min ischemia and 40-min reperfusion. During ischemia, the decrease in PCr and intracellular pH were similar in A 3 AR-overexpressor and wild-type hearts (Fig. 2) . However, ischemic ATP depletion was delayed in the A 3 AR-overexpressor hearts compared with wildtype hearts, the rate of fall of ATP being Ϫ3.6% initial ATP/min in A 3 AR-overexpressor hearts compared with Ϫ5.1% initial ATP/min in wild-type hearts during the first 15 min of ischemia. During reperfusion, recovery of the energy metabolites ATP and PCr was faster in A 3 AR-overexpressor hearts than wild-type hearts (Fig.  2) . In addition, postischemic contractile dysfunction was lower in A 3 AR-overexpressor hearts than wildtype hearts (Fig. 1 ). It appears, therefore, that overexpression of the A 3 AR results in short-term preservation of ATP levels during ischemia and protects against postischemic contractile and energetic dysfunction.
Effect of Pacing on Contractility, Energetics, and Postischemic Dysfunction in A 3 AR-Overexpressor Versus Wild-Type Hearts
Depressed preischemic heart rate and contractility can lead to decreased ATP utilization and increased postischemic recovery (17) . To determine whether depressed heart rate was responsible for the ischemic ATP preservation and cardioprotection in the A 3 AR overexpressors, hearts were paced at 480 beats/min throughout the protocol. Pacing increased LVDP, ϩdP/ dt, and ϪdP/dt in A 3 AR-overexpressor hearts but, surprisingly, had no effect on these parameters in wildtype hearts (Table 1) . Although surprising, this finding is consistent with recent studies indicating that the force-frequency response is biphasic in mouse hearts. It has been shown that increasing heart rate in the range of 300-400 beats/min results in increased developed pressure, whereas increasing heart rate from 400 beats/min upward either has no effect or decreases developed pressure (9, 16) . The peak of the force-frequency curve in mice varies slightly with different experimental models (9, 16) . Our results would suggest a positive force-frequency relationship in the 300-to 400 beats/min range and a plateau in the 400-to 500 beats/min range in isolated mouse hearts, consistent with a recent study by Headrick et al. (13) .
Pacing itself increased the rate of ischemic ATP depletion from Ϫ3.6 to Ϫ5.4% initial ATP/min in A 3 ARoverexpressor hearts and from Ϫ5.1 to Ϫ7.1% initial ATP/min in wild-type hearts over the 15-min ischemic period. As can be seen from these values, despite the equivalent contractility in paced A 3 AR-overexpressor hearts compared with paced wild-type hearts, ATP depletion remained slower in the A 3 AR-overexpressor hearts at Ϫ5.4% initial ATP/min in paced A 3 AR-overexpressor hearts compared with Ϫ7.1% initial ATP/ min in paced wild-type hearts. Likewise, the postischemic recovery of ATP, PCr, and contractile function remained greater in the paced A 3 AR-overexpressor hearts compared with paced wild-type hearts (Figs. 1  and 3) . From these results, we can conclude that the preservation of ischemic ATP and the reduced postischemic contractile and energetic dysfunction in the A 3 AR-overexpressor hearts were not due to the decreased basal heart rate and contractility induced by A 3 AR overexpression.
Effect of A 3 AR Inhibition on Contractility, Energetics, and Postischemic Dysfunction in A 3 AR-Overexpressor Versus Wild-Type Hearts
To determine whether the ischemic ATP preservation and cardioprotection observed in A 3 AR-overexpressor hearts was due specifically to A 3 AR signaling, and not to secondary alterations induced by the presence of the transgene, paced hearts were pretreated with 60 nmol/l of a canine A 3 AR-specific inhibitor, MRS-1220. The concentration of MRS-1220 was chosen on the basis of the MRS-1220 inhibitor constant for the canine A 3 AR of 6 nmol/l (18) and on preliminary doseresponse studies in isolated hearts. The 60 nmol/l concentration had no effect on contractile function; LVDP, ϩdP/dt, and ϪdP/dt being the same before and after infusion of 60 nmol/l MRS-1220 in both paced wild-type and paced A 3 AR-overexpressor hearts (Table 1) .
Pretreatment with MRS-1220 completely abolished the ischemic ATP preservation and the greater postischemic recovery of ATP, PCr, and contractile function in the A 3 AR-overexpressor compared with wild-type hearts (Figs. 1 and 3 ). It appears, therefore, that the preservation of ischemic ATP levels and the protection from postischemic contractile and energetic dysfunction observed in the A 3 AR-overexpressor hearts were mediated specifically by the A 3 AR and were not due to adaptive alterations induced by long-term A 3 AR overexpression.
In summary, we have demonstrated that cardiacspecific overexpression of the A 3 AR results in decreased basal heart rate and contractility, short-term ischemic ATP preservation, and protection from postischemic contractile and energetic dysfunction. Depressed preischemic contractility can itself be protective. However, by pacing hearts at a rate that resulted in similar contractile function in the A 3 AR-overexpressor hearts as in wild-type hearts, we demonstrated that the depressed contractility had no role in the ischemic ATP preservation and cardioprotection in the A 3 AR-overexpressor hearts. By pretreating hearts with the A 3 AR-specific inhibitor MRS-1220, we also demonstrated that the energetic and functional effects observed in the A 3 AR-overexpressor hearts were mediated specifically by the A 3 AR. Together, these results imply that myocardial A 3 AR signaling is cardioprotective and leads to preservation of ischemic ATP levels. Because cardioprotection was coincident with decreased ATP depletion in all our experiments, the decreased ATP depletion may be the mechanism by which A 3 AR signaling leads to cardioprotection. Interestingly, decreased ATP depletion during ischemia was also found to be coincident with protection in A 1 ARoverexpressor hearts (12) , suggesting that the A 3 AR and A 1 AR may mediate protection via a common mechanism of energy preservation.
To our knowledge, this is the first study to assess the energetic consequences of cardiac-specific overexpression of the A 3 AR and is also the first study to determine the effects of A 3 AR overexpression on postischemic contractile dysfunction after short-term ischemia. Our results support the use of cardiac-specific expression techniques. Previous studies showed that, although A 3 AR agonists can have direct beneficial effects on isolated hearts (11), A 3 AR signaling in mast cells may be detrimental to the myocardium via proinflammatory mechanisms (21, 25, 30) , such that systemic A 3 AR inhibition can actually be protective (3, 10) . These studies highlight the necessity for cardiac-specific A 3 AR targeting in future therapeutic approaches and also highlight the possible complications of using systemic A 3 AR agonists as cardioprotective agents.
